Latest News & Features
Asia
India’s patent office has published final guidelines for examining biotechnology patents, after accepting comments on a draft version published in December. 2 April 2013
Biotechnology
In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains. 1 April 2013
Asia
To read much of the reaction to recent pharmaceutical rulings in India, you might think that the country is waging a war against Western innovation. But while there is certainly cause for concern, that’s not the whole story, as LSIPR finds out. 1 April 2013
Asia
There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain. 1 April 2013
Asia
Therapeutic substances used under the folk medicine practices of what is known as ‘traditional knowledge’ are protected by special provisions under Indian patent law. Archana Shanker and Vidisha Garg explore the pros and cons. 1 April 2013
Americas
The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium
on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system. 1 April 2013
Americas
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives. 1 April 2013
Americas
Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate. 1 April 2013
Americas
On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications. 1 April 2013
Europe
While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains. 1 April 2013